The Top 5 Biosimilars Articles for the Week of July 15

The Center for Biosimilars® recaps the top stories for the week of July 15, 2019.


Hi, I’m Jaime Rosenberg for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of July 15, 2019.

Number 5: Coherus BioSciences says that, 6 months after launching its biosimilar pegfilgrastim, it has produced more than 400,000 syringes of the product.

Number 4: A rheumatology practice says that using a value-based pathway for rheumatoid arthritis has led to increased biosimilar use.

Number 3: Recent research shows that the Bipartisan Budget Act resulted in a decrease in out-of-pocket spending for biosimilars, but out-of-pocket spending on specialty generics has risen.

Number 2: According to the Congressional Budget Office, enacting the Lower Health Care Costs Act would reduce the deficit by more than 7 billion dollars by 2029.

Number 1: Celltrion announced that it is launching its first clinical trial of biosimilar CT-P39 referencing Xolair. The company plans to commercialize the biosimilar in 2022.

Finally, last week, our e-newsletter asked whether you think that shifting away from buy-and-bill practices for oncology drugs would help reduce costs.

To view results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit